Susvimo can help people with diabetic retinopathy (DR) maintain their vision and prevent progression to blindness with only ...

The secret to a successful cataract surgery in diabetics lies in making informed decisions. Instead of being influenced by ...

The Food and Drug Administration (FDA) has approved Susvimo ® (ranibizumab injection) for the treatment of patients with diabetic retinopathy who have previously responded to at least 2 intravitreal ...

Thanks to advancements in early detection and treatment options, it's possible to live a long and healthy life after being ...

One-year results from the Pavilion study showed patients who received Susvimo (ranibizumab) refilled every nine months ...

Susvimo is the first and only FDA-approved, continuous delivery treatment shown to maintain vision in people with DR with ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

The FDA approved Susvimo 100 mg/mL to treat diabetic retinopathy, according to a press release from Genentech.The approval was supported by positive 1-year data from the phase 3 Pavilion study in ...

Key trends include advanced multicolor laser adoption and increased outpatient treatments. Challenges include reimbursement issues and competition from alternative therapies. Leading players like ...

Susvimo is also approved to treat diabetic macular edema and age-related macular degeneration, and the medication, ranibizumab, is delivered through an ocular implant that is refilled every nine ...

Basel: Roche has received approval from the US Food and Drug Administration (FDA) for Susvimo (ranibizumab injection) 100 ...